Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 2/20 | 0.42 |
| ▸ | PYGM | P11217 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8304087 | 0.86 | HSD17B10 (0.55) | HSD17B10HTTBRD4CREBBPGAA | |
| SCHEMBL7073390 | 0.83 | GAA (0.42) | HSD17B10HTTEGFRBRD4CREBBP | |
| SCHEMBL3710805 | 0.82 | HSD17B10 (0.49) | HSD17B10EGFRBRD4CREBBPPYGL | |
| SCHEMBL4324384 | 0.82 | PYGL (0.43) | HSD17B10HTTBRD4CREBBPPYGL | |
| SCHEMBL7072903 | 0.82 | USP2 (0.41) | HSD17B10HTTGAAUSP2MEN1 | |
| SCHEMBL5779777 | 0.82 | HSD17B10 (0.43) | HSD17B10HTTEGFRBRD4GAA | |
| SCHEMBL5811684 | 0.82 | HSD17B10 (0.41) | HSD17B10HTTEGFRBRD4GAA | |
| SCHEMBL30563086 | 0.81 | ALDH1A1 (0.45) | HSD17B10BRD4CREBBPPYGLPYGM | |
| SCHEMBL5140200 | 0.81 | ALDH1A1 (0.45) | HSD17B10BRD4CREBBPPYGLPYGM | |
| SCHEMBL7078712 | 0.81 | POLB (0.42) | HSD17B10HTTPYGLPYGMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579363-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2009-08-25 | — | — | US | disclosed |
| EP-1651643-A4 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC (BM) | 2008-10-08 | — | — | EP | disclosed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | disclosed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
| EP-1651643-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| EP-1615890-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | IRM LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005011611-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-3974165-A | Hypotensive agents | BRISTOL-MYERS COMPANY (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | PDF, FDPS, DCTPP1 | HSD17B10 2730/4885HTT 1644/4885EGFR 4413/4885 |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | PDF, FDPS, DCTPP1 | HSD17B10 1950/4885HTT 3166/4885EGFR 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.